S
Susan G. Hilsenbeck
Researcher at Baylor College of Medicine
Publications - 339
Citations - 29288
Susan G. Hilsenbeck is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 86, co-authored 313 publications receiving 26611 citations. Previous affiliations of Susan G. Hilsenbeck include University of Texas System & National University of Singapore.
Papers
More filters
Journal ArticleDOI
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Xiaoxian Li,Michael T. Lewis,Jian Huang,Carolina Gutierrez,C. Kent Osborne,Meng Fen Wu,Susan G. Hilsenbeck,Anne Pavlick,Xiaomei Zhang,Gary C. Chamness,Helen Wong,Jeffrey M. Rosen,Jenny C. Chang +12 more
TL;DR: These studies provide clinical evidence for a subpopulation of chemotherapy-resistant breast cancer-initiating cells and, in combination with conventional therapy, specific pathway inhibitors may provide a therapeutic strategy for eliminating these cells to decrease recurrence and improve long-term survival.
Journal ArticleDOI
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton,Xiaoxian Li,Melissa D. Landis,J. Michael Dixon,Veronique Neumeister,Ashley Sjolund,David L. Rimm,Helen Wong,Angel Rodriguez,Jason I. Herschkowitz,Cheng Fan,Xiaomei Zhang,Xiaping He,Anne Pavlick,M. Carolina Gutierrez,Lorna Renshaw,Alexey Larionov,Dana Faratian,Susan G. Hilsenbeck,Charles M. Perou,Michael T. Lewis,Jeffrey M. Rosen,Jenny C. Chang +22 more
TL;DR: Supporting evidence is provided that the residual breast tumor cell populations surviving after conventional treatment may be enriched for subpopulations of cells with both tumor-initiating and mesenchymal features.
Journal ArticleDOI
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein,Anna Tsimelzon,Graham M. Poage,Kyle R. Covington,Alejandro Contreras,Suzanne A. W. Fuqua,Michelle I. Savage,C. Kent Osborne,Susan G. Hilsenbeck,Jenny C. Chang,Gordon B. Mills,Ching C. Lau,Powel H. Brown +12 more
TL;DR: There are four stable TNBC subtypes characterized by the expression of distinct molecular profiles that have distinct prognoses, and novel subtype-specific targets that can be targeted in the future for the effective treatment of TNBCs are identified.
Journal ArticleDOI
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
Jenny C. Chang,Eric C. Wooten,Anna Tsimelzon,Susan G. Hilsenbeck,M. Carolina Gutierrez,Richard M. Elledge,Syed K. Mohsin,C. Kent Osborne,Gary C. Chamness,D. Craig Allred,Peter O'Connell +10 more
TL;DR: It is postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel, and these molecular profiles could allow development of a clinical test for docetAXel sensitivity, thus reducing unnecessary treatment for women with breast cancer.
Journal ArticleDOI
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer
C. Kent Osborne,Valerie Bardou,Torsten A. Hopp,Gary C. Chamness,Susan G. Hilsenbeck,Suzanne A. W. Fuqua,Jiemin Wong,D. Craig Allred,Gary M. Clark,Rachel Schiff +9 more
TL;DR: The antitumor activity of tamoxifen in patients with breast cancer may be determined, in part, by tumor levels of AIB1 and HER-2, which may be an important diagnostic and therapeutic target.